Venkat Mocherla

for both founders and for patients and for, you know, clinical and administrative leaders in healthcare, which is, I think, the first kind of trend that I think is so powerful for AI is we talk about all these sort of magical applications like chat GPT or perplexity or whatever you're using. Or, you know, if you come to San Francisco, it's a pretty magical experience.

for both founders and for patients and for, you know, clinical and administrative leaders in healthcare, which is, I think, the first kind of trend that I think is so powerful for AI is we talk about all these sort of magical applications like chat GPT or perplexity or whatever you're using. Or, you know, if you come to San Francisco, it's a pretty magical experience.

And now it's in Arizona and a couple of the markets, which is, getting into a Waymo before all of these sort of applied AI applications, you really have to figure out the data piece. And I think we don't talk about that enough. And so, you know, after the high-tech act, we really kicked off. I think we, you know, the example I give is like the human genome project, right.

And now it's in Arizona and a couple of the markets, which is, getting into a Waymo before all of these sort of applied AI applications, you really have to figure out the data piece. And I think we don't talk about that enough. And so, you know, after the high-tech act, we really kicked off. I think we, you know, the example I give is like the human genome project, right.

Where we got to sequence all the DNA to throw out all these magical medicines we can do, um, you know, with genetics. I think there's a corollary there of actually sequencing, I call it the business genome, which is like, how do you capture the data, whether it's from other systems or record like the EMR, Epic, whether it's ERP systems. There's a lot of mapping.

Where we got to sequence all the DNA to throw out all these magical medicines we can do, um, you know, with genetics. I think there's a corollary there of actually sequencing, I call it the business genome, which is like, how do you capture the data, whether it's from other systems or record like the EMR, Epic, whether it's ERP systems. There's a lot of mapping.

If you remember back in the day, if you think about using Google Maps, there's a car that's going across every street in America and capturing that picture. There's that work of sequencing the business genome that I think it has made all of these companies even possible in these applications. So that's trend one that I think is so powerful.

If you remember back in the day, if you think about using Google Maps, there's a car that's going across every street in America and capturing that picture. There's that work of sequencing the business genome that I think it has made all of these companies even possible in these applications. So that's trend one that I think is so powerful.

I think trend two that I think is so interesting and fascinating is people's superpowers. So what do I mean by that? Clinicians are incredibly burnt out. Why are they burnt out? A big part of that driver is what we call pajama time. They're doing clinical notes after seeing a really busy day of patients.

I think trend two that I think is so interesting and fascinating is people's superpowers. So what do I mean by that? Clinicians are incredibly burnt out. Why are they burnt out? A big part of that driver is what we call pajama time. They're doing clinical notes after seeing a really busy day of patients.

And instead of now typing into the keyboard, you have these ambient devices that can give, basically take their notes on their behalf and summarize it and input it into the EMR with some supervision.

And instead of now typing into the keyboard, you have these ambient devices that can give, basically take their notes on their behalf and summarize it and input it into the EMR with some supervision.

Same thing on the administrative side, like how do you give people superpowers around managing your, you know, or, you know, doing block optimization if you're, if you're Coventus or in the case of Midstream, how are you thinking about financial decisions that are across the, you know, very complex supply chain or the pharmacy or managed care and other areas?

Same thing on the administrative side, like how do you give people superpowers around managing your, you know, or, you know, doing block optimization if you're, if you're Coventus or in the case of Midstream, how are you thinking about financial decisions that are across the, you know, very complex supply chain or the pharmacy or managed care and other areas?

So I think, you know, this era of superpowers has sort of unleashed a big opportunity set. The third thing I'll sort of say from a patient perspective is there's a, you know, I think about it as like autonomy in healthcare. So, you know, I talked about the Waymo example where, you know, you have, you know, the self-driving world, actually, you know, this is inspired by DARPA,

So I think, you know, this era of superpowers has sort of unleashed a big opportunity set. The third thing I'll sort of say from a patient perspective is there's a, you know, I think about it as like autonomy in healthcare. So, you know, I talked about the Waymo example where, you know, you have, you know, the self-driving world, actually, you know, this is inspired by DARPA,

they put a framework around how do you think about self-driving cars. So there's a framework that starts with an L1, level one. They give it some basic, you know, cruise control type stuff to like L5, which is like, you know, your fully autonomous car.

they put a framework around how do you think about self-driving cars. So there's a framework that starts with an L1, level one. They give it some basic, you know, cruise control type stuff to like L5, which is like, you know, your fully autonomous car.

I think we're going through that journey right now from a patient perspective because, you know, how do you think about this very reactive system we sit in today compared to,

I think we're going through that journey right now from a patient perspective because, you know, how do you think about this very reactive system we sit in today compared to,